- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
B&L's newest excimer laser approved
Rochester, NY-The FDA has approved Bausch & Lomb's 100 Hzexcimer laser, the 217z100, for use as part of the Zyoptixpersonalized laser vision-correction system for refractive surgery.
Rochester, NY-The FDA has approved Bausch & Lomb's 100 Hz excimer laser, the 217z100, for use as part of the Zyoptix personalized laser vision-correction system for refractive surgery.
The combination of beam diameters and laser speed of the 217z100 makes it among the fastest laser vision correction treatment times available in the United States, according to the company. The laser operates at twice the speed of the Bausch & Lomb system currently on the U.S. market, the company said.
"The 217z100 laser reduces treatment time with the Bausch & Lomb Zyoptix system by half. This reduction in treatment time comes on the heels of dramatic efficiency gains already achieved through a number of recent upgrades to the Zyoptix system," said Bob Anello, Bausch & Lomb's director of refractive marketing.
